Altre lingue Mineralys Therapeutics, Inc.

Azioni

MLYS

US6031701013

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 13/05/2024			Variaz. 5gg	Var. 1 gen.
12,93 ^USD	-4,36%		-5,96%	+50,35%

09/05	Transcript : Mineralys Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Mineralys Therapeutics, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Mineralys Therapeutics : Corporate Overview May 2024	13/05
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05
Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference	06/05
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024	02/05
Mineralys Therapeutics, Inc. Announces Alexander Asam Informs That His Decision Not to Stand for Re-Election to the Board	04/04
Mineralys Therapeutics Files Mixed-Securities Shelf Registration	21/03
Mineralys Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Mineralys Therapeutics : Corporate Overview March 2024	21/03
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	21/03
Mineralys Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
North American Morning Briefing : Investors -2-	21/03
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024	13/03
Sector Update: Health Care Stocks Ease in Late Afternoon	08/02
Sector Update: Health Care	08/02
Mineralys Therapeutics Secures $120 Million Financing Through Private Placement; Shares Rise	08/02
Mineralys Therapeutics Announces $120 Million Private Placement Financing	08/02
Mineralys Therapeutics, Inc. announced that it expects to receive $119.999925 million in funding from TCG Crossover Management, LLC, OrbiMed Advisors LLC, RA Capital Management, L.P., Samsara BioCapital LLC, VR Adviser, LLC	07/02
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference	29/01
Mineralys Therapeutics Names Minji Kim as Chief Business Officer	04/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Mineralys Therapeutics, Inc.

Azioni

MLYS

US6031701013

Altre lingue

Filtri